LY-320135
Benzofuran CB1 antagonist, Ki 224 nM and more than 70-fold selective over CB2.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₄H₁₇NO₄
CAS 176977-56-3
- Family
- ECS pharmacological toolAntagonist or inverse agonist
- Molar mass
- 383.40 g/mol
Updated on
In plain terms
LY-320135 blocks the CB1 receptor without resembling other known blockers chemically. It was used to reveal an unexpected behaviour of this receptor: under certain conditions it can stimulate an enzyme it normally inhibits. It is a laboratory tool; no study in humans was found.
Receptors and activity
Target network
- Blocks or inhibits
- Binds or modulates
The lower the cited value, the closer the target sits to LY-320135: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of LY-320135.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1AntagonistKi = 224 nM44 out of 100
Felder et al., J Pharmacol Exp Ther 1998 (new tab) · binding at CB1 stably expressed in a cell line (224 nM) and on cerebellar membranes (203 nM); species not specified in the abstract; reverses the inhibition of adenylate cyclase by anandamide
- CB2Binding (function not established)no measured value cited
Ki greater than 10 µM (stable line and spleen membranes); CB1 selectivity greater than 70-fold (Felder et al. 1998)
Pharmacology
LY-320135 is a CB1 receptor antagonist described in 1998 by Felder and colleagues, with a benzofuran structure. Its selectivity is clear: Ki 224 nM at CB1 stably expressed in cell lines versus above 10 µM at CB2, more than 70-fold, with similar values on cerebellum and spleen membranes. Its main interest is methodological. By treating CHO cells expressing CB1 with pertussis toxin, the authors attenuated anandamide-mediated inhibition of adenylate cyclase and unmasked a stimulatory effect of anandamide on the enzyme; LY320135 blocked this stimulatory component, attributing it to the CB1 receptor (Felder et al. 1998). The compound also blocks the WIN 55212-2-mediated inhibition of N-type calcium channels and activation of inwardly rectifying potassium channels. The authors describe it as a promising lead for new cannabinoid antagonists of novel structure. These results come from cells and membranes; no study in whole animals or in humans was found.
Key sources.
- Felder CC et al. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther, 1998 (new tab)PMID 9435190
- Meye FJ et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry, 2013 (new tab)PMID 23070073
- PubChem, LY-320135, CID 5311257 (identifiers and properties) (new tab)
History
- Source
- An entirely synthetic compound with no natural occurrence. It is known as a pharmacological research reagent; no clinical development or human use was found in the sources consulted.
Origin
Research tool
No biological pathway: LY-320135 is a synthetic compound with a benzofuran core, unrelated to the plant cannabinoid pathway.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found.
- France
Not classified: LY-320135 is not on the ANSM consolidated list of narcotics (updated 16/02/2026). On a literal reading, the clause on molecules derived from the benzofuran nucleus requires an alpha-ethylamine group, absent from this benzofuran ketone; no other generic family of the list applies. No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Antagonist or inverse agonist
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Felder CC et al. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther, 1998 (new tab)PMID 9435190
- Meye FJ et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry, 2013 (new tab)PMID 23070073
- PubChem, LY-320135, CID 5311257 (identifiers and properties) (new tab)
Identifiers
Names
- IUPAC name
- 4-[6-methoxy-2-(4-methoxyphenyl)-1-benzofuran-3-carbonyl]benzonitrile
- Other names
- LY320135 · LY 320135
Identifiers
- Formula
- C₂₄H₁₇NO₄
- CAS
- 176977-56-3
- PubChem CID
- 5311257(new tab)
- InChIKey
- RYNSGDFWBJWWSZ-UHFFFAOYSA-N
- SMILES
- COC1=
CC= C(C= C1) C2= C(C3= C(O2) C= C(C= C3) OC) C(= O) C4= CC= C(C= C4) C#N
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.